RED4MS: teaching the immune system tolerance with modified red blood cells

What is being studied

RED4MS studied CLS12311, made from a person's own red blood cells coupled to peptides, as a way to promote antigen-specific immune tolerance in relapsing multiple sclerosis (MS). A separate phase Ib study reported in PNAS in August 2026 also examined peptide-coupled red blood cells; it is a different cohort, not RED4MS. The 7 October 2026 Science Advances paper investigates how the approach works in EAE mice.

Research stage

Phase 1 study in people

NCT06430671 is completed; current broader programme status is not established

What we know so far

The registered RED4MS study NCT06430671 is completed. The registry lists 11 enrolled; 9 received CLS12311, and summary results were first posted on 8 June 2026. Cellerys's RED4MS lay summary reports generally good tolerability across the tested doses, mostly mild adverse events, one serious event judged unrelated to treatment, and two MS relapses judged unrelated. This small safety study cannot establish whether CLS12311 prevents MS activity. Separately, the PNAS phase Ib paper reports tolerability observations and changes in antigen-specific regulatory T cells; those findings belong to its own cohort and do not establish benefit for people with MS. The October Kupffer-cell finding is from mice. The current status of the broader programme is unknown.

What this means for patients today

CLS12311 remains an investigational approach, not an established available MS treatment. The small early human study does not show reliable benefit for people with MS, and the mouse mechanism does not establish human benefit, safety or myelin repair. The completed trial is not accepting participants. Access or reimbursement in Greece is not established.